|
|
||||||||
1 Respiratory Muscle Laboratory, Royal Brompton Hospital, and 2 Dept of Respiratory Medicine, King's College Hospital, London, UK
CORRESPONDENCE: N. Hopkinson, Respiratory Muscle Laboratory, Royal Brompton Hospital, London SW3 6NP, UK. Fax: 44 2073518939. E-mail: n.hopkinson@ic.ac.uk
Keywords: Chronic obstructive pulmonary disease, corticosteroids, diaphragm, exercise, magnetic stimulation, quadriceps
Received: December 16, 2003
Accepted March 14, 2004
N. Hopkinson is funded by the Wellcome Trust, W. Man by the Medical Research Council, A. Nickol by the British Lung Foundation, E. Ross by the Cystic Fibrosis Trust and M. Dayer by the British Heart Foundation. M. Polkey's COPD research is part of the European Union European network for investigating the global mechanisms of muscle abnormalities in COPD (ENIGMA) Project (Grant no: QLK6-CT-2002-02285).
Prospective data to support the hypothesis that corticosteroids are a significant cause of muscle weakness in patients with chronic obstructive pulmonary disease (COPD) are lacking.
The authors studied respiratory and quadriceps muscle function, using both volitional techniques and magnetic nerve stimulation, as well as measuring metabolic parameters during incremental cycle ergometry, in 25 stable COPD patients. The forced expiratory volume in one second was 37.6±21.4 % predicted, before and after a 2-week course of o.d. prednisolone 30 mg. Quadriceps strength was also assessed in 15 control patients on two occasions.
Only two patients met the British Thoracic Society definition of steroid responsiveness. There was no change either in sniff transdiaphragmatic pressure (pre: 96.8±19.7 cmH2O; post: 98.6±22.4 cmH2O) or in twitch transdiaphragmatic pressure elicited by bilateral anterolateral magnetic phrenic-nerve stimulation (pre: 16.8±9.1 cmH2O; post: 17.9±10 cmH2O). Quadriceps twitch force did not change significantly either in the steroid group (pre: 9.5±3.1 kg; post: 8.9±3.7 kg) or in the control patients (pre: 8.1±2.7 kg; post: 7.9±2.2 kg). There were no changes in either peak or isotime ventilatory and metabolic parameters during exercise.
In conclusion, in stable patients with chronic obstructive pulmonary disease, a 2-week course of 30 mg prednisolone daily does not cause significant skeletal muscle dysfunction or alter metabolic parameters during exercise.
This article has been cited by other articles:
![]() |
M. Van Vliet, M. A. Spruit, G. Verleden, A. Kasran, E. Van Herck, F. Pitta, R. Bouillon, and M. Decramer Hypogonadism, Quadriceps Weakness, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1105 - 1111. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Couillard and C. Prefaut From muscle disuse to myopathy in COPD: potential contribution of oxidative stress Eur. Respir. J., October 1, 2005; 26(4): 703 - 719. [Abstract] [Full Text] [PDF] |
||||
![]() |
W D-C Man, N S Hopkinson, F Harraf, D Nikoletou, M I Polkey, and J Moxham Abdominal muscle and quadriceps strength in chronic obstructive pulmonary disease Thorax, September 1, 2005; 60(9): 718 - 722. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38. [Full Text] [PDF] |
||||
![]() |
M.I. Polkey, R. Farre, and A.T. Dinh-Xuan Respiratory monitoring: revisiting classical physiological principles with new tools Eur. Respir. J., November 1, 2004; 24(5): 718 - 719. [Full Text] [PDF] |
||||
![]() |
W.D-C. Man, J. Moxham, and M.I. Polkey Magnetic stimulation for the measurement of respiratory and skeletal muscle function Eur. Respir. J., November 1, 2004; 24(5): 846 - 860. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |